To help, Equinox has launched a one-of-a-kind, research-backed GLP-1 protocol
Preliminary results are encouraging for weight loss and glycemic control, but its long-term effects are unknown
In contrast, Novo Nordisk boasts a much larger market cap of roughly $219 billion and a lower P/E ratio of 13-14, but its stock has faced headwinds, with some analysts issuing 'Hold' ratings and lower price targets around $56-$59, reflecting concerns about market share and pricing
Overall benefit-risk assessments Statins consistently demonstrated superior effectiveness over control treatments in lowering the risk of all-cause mortality (OR 0.87, 95% CI 0.820.92) and major coronary events (OR 0.69, 95% CI 0.640.75) across various populations
Experiencing shopping with us is easy and fun
I love tirzepatide, Chrisley said